MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

The Impact of Metabolic Syndrome on Parkinson’s Disease Progression: A Systematic Review

T. Denicol, C. Dagostini, MF. Felippe, G. Guindani Maia, G. Dal Alba, J. Sánchez León, A. Hilbig, C. Mello Rieder (Porto Alegre, Brazil)

Meeting: 2025 International Congress

Keywords: Parkinson’s

Category: Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales

Objective: We aimed to identify the impact of Metabolic syndrome (MS) in motor and non-motor symptoms of Parkinson’s disease (PD).

Background: PD is a common neurodegenerative disease. With the aging of the population, there is a tendency for an increase in the number of affected individuals. More recent studies have demonstrated that diseases that increase the risk of cardiovascular events may act as risk factors (RF) for PD. MS is a set of RF for the manifestation of cardiac and cerebrovascular diseases; therefore, it must be understood whether the presence of MS in patients with PD can alter the course of the disease, leading to greater impairment of motor and non-motor symptoms (NMS) compared to patients with PD alone, without MS.

Method: Five databases were searched between February and March 2025. Patients with PD (≥18 years old), with or without MS, were included from studies published between January 2010 and February 2025 where the progression of Parkinson’s Disease could be analyzed through scales/tests used in the follow-up of these patients (PROSPERO ID: CRD420251010170). GRADE was utilized to assess certainty (or confidence) in the bodies of evidence produced by the review.

Results: Seven studies were included (2 randomized controlled trials and 5 observational studies), totaling 65,047 patients, of whom 2,062 had PD and 441 also had MS. Ages ranged from 42 to 82 years across five countries. In pooled analysis, four studies assessed UPDRS/MDS-UPDRS progression in PD patients with MS: two reported slight motor worsening, while the others found no change. Furthermore, NMS were evaluated using various tests, such as MoCA, MDRS, SDMT, NMSS, and PDSS-2. Two studies detected mild cognitive decline, while one found no cognitive changes but reported significantly worse NMS in PD-MS patients. One study examined the risk of PD in MS patients and found no association but did identify a link with hypertension or diabetes mellitus alone. Overall, the studies showed a low risk of bias, with minor concerns in a few areas.

Conclusion: MS may contribute to worse progression of PD, with some studies reporting slight motor decline and more severe non-motor symptoms in PD-MS patients. However, findings were inconsistent, and the overall impact of MS on disease progression remains unclear. Given the limited and heterogeneous data, further studies are needed to better understand the influence of MS on PD outcomes.

References: 1. Sharma S, Oakes D, Eberly S, Singer C, Lowell J, Simuni T. Association between metabolic syndrome and progression in Parkinson’s disease. Clin Epidemiol Glob Health. 2023;24:101409. doi:10.1016/j.cegh.2023.101409.
2. Leehey M, Luo S, Sharma S, Wills AMA, Bainbridge JL, Wong PS, et al. Association of metabolic syndrome and change in Unified Parkinson’s Disease Rating Scale scores. Neurology. 2017;89(17):1789-1794. doi:10.1212/WNL.0000000000004572.
3. Doiron M, Langlois M, Dupré N, Simard M. The influence of vascular risk factors on cognitive function in early Parkinson’s disease. Int J Geriatr Psychiatry. 2017;32(12):1247-1254. doi:10.1002/gps.4735.
4. Shi Y, Zhang X, Feng Y, Yue Z. Association of metabolic syndrome and its components with Parkinson’s disease: a cross-sectional study. BMC Endocr Disord. 2024;24:92. doi:10.1186/s12902-024-01623-3.
5. Laudisio A, Lo Monaco MR, Vetrano DL, Pisciotta MS, Bentivoglio AR, Bernabei R, Zuccalà G. Association of metabolic syndrome with falls in patients with Parkinson’s disease. Clin Nutr. 2016;35(5):1142-1147. doi:10.1016/j.clnu.2016.02.004.
6. Meléndez-Flores JD, Castillo-Torres SA, Cerda-Contreras C, Chávez-Luévanos B, Estrada-Bellmann I. Clinical features of metabolic syndrome in patients with Parkinson’s disease. Rev Neurol. 2021;72(1):9-15. doi:10.33588/rn.7201.2020323.
7. Schelp AO, Mendes-Chiloff CL, Bazan R, Paduan VC, Pioltini AB. Metabolic syndrome and dementia associated with Parkinson’s disease: impact of age and hypertension. Arq Neuropsiquiatr. 2012;70(2):114-118. doi:10.1590/S0004-282X2012000200014.

To cite this abstract in AMA style:

T. Denicol, C. Dagostini, MF. Felippe, G. Guindani Maia, G. Dal Alba, J. Sánchez León, A. Hilbig, C. Mello Rieder. The Impact of Metabolic Syndrome on Parkinson’s Disease Progression: A Systematic Review [abstract]. Mov Disord. 2025; 40 (suppl 1). https://www.mdsabstracts.org/abstract/the-impact-of-metabolic-syndrome-on-parkinsons-disease-progression-a-systematic-review/. Accessed October 5, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2025 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-impact-of-metabolic-syndrome-on-parkinsons-disease-progression-a-systematic-review/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley